PubMed Health⌕ Search

Biomedical subjects

G Bailly

Publications and source records attributed to G Bailly.

13 recordsLinked to original sources
PubMed1991

Saccade metrics in multiple sclerosis: versional velocity disconjugacy as the best clue?

We studied the parameters (latency, amplitude, peak velocity) of horizontal saccades in 32 patients with multiple sclerosis (MS) and 20 healthy, age matched control subjects. Saccades were recorded by direct-current electro-oculography technique (EOG). The patients were divided in 2 groups according to the absence or the presence of clinical internuclear ophthalmoplegia (INO). In both groups, we found increased latency, hypometria and reduced velocity. The disconjugacy of saccades was measured by calculating the ratio of abduction and adduction peak velocities (the versional disconjugacy index: VDI). Though the absolute value of this index might be dependent on the recording technique, its variation is not. Interestingly, the VDI was significantly increased in the groups of MS patients without clinical INO, indicating a more severe slowing in adduction. We concluded that VDI may be a very useful index in detecting subtle disorders in saccades conjugacy.

Electrooculography↗
PubMed1988

Combination of recombinant interferon alpha-2a and vinblastine in advanced renal cell cancer.

Among 40 evaluable patients with metastatic renal cell cancer treated by high-dose interferon alpha-2a in combination with vinblastine, the authors have observed a 42.5% response rate. The 8 months' median duration of remissions is relatively short but some patients experience very long remissions, lasting many months after discontinuation of therapy. The survival of responding patients is significantly longer than the survival of nonresponders. The diverging results of other studies of the same combination are discussed; its efficacy is certainly dependent on the type of interferon, on the dose actually administered, and on the compliance to this often poorly tolerated treatment.

Adult↗
PubMed1988

Treatment of superficial bladder tumors with intravesical recombinant interferon alpha-2a.

In a prospective study, the toxicity and efficacy of an instillation therapy with recombinant interferon alpha-2a (rIFN-alpha-2a) were evaluated in 12 patients with superficial bladder tumors. Treatment consisted of 8 weekly instillations of 54 X 10(6) IU rIFN-alpha-2a in 50 ml saline. Two weeks after completion of the instillation therapy, the tumor status was assessed with cystoscopy, biopsy and bladder wash-out cytology. Two partial responses, 1 no change and 2 progressive disease were seen in the 5 patients with TA tumors. In the 4 patients with carcinoma in situ, 1 complete response, 1 partial response and 2 no change were observed. Three patients suffered from carcinoma in situ and superficial papillary tumors, 1 showed complete response of the carcinoma in situ but no change of the TA tumor, the other 2 patients showed progressive disease. Three patients with partial response received a follow-up combination therapy with interferon intravesically and etretinate orally (25 mg/day). These patients presented progressive disease or no change 10 weeks after starting the follow-up combination therapy. During the treatment period, no side effects of interferon or changes of the serum interferon levels were observed. The treatment results are considered unsatisfactory; nevertheless, some activity after intravesical administration of interferon (mainly in patients with carcinoma in situ) could be demonstrated. Since the cytotoxic and antiproliferative effects seem to be dose-dependent, further studies might be done using higher interferon dosages and shorter treatment intervals.

Administration, Intravesical↗
PubMed1987

[Treatment of metastatic renal adenocarcinomas with combined recombinant alpha-2a interferon and vinblastine].

The results of treatment of metastatic renal cell carcinoma have so far been very poor. Many phase II studies have shown that interferon alpha therapy is active in a significant proportion of patients (approximately 10 to 15% complete and partial remission). In the hope of improving these results we have conducted a phase I-II study of the combination of interferon alpha-2a and vinblastine in 21 patients with metastatic renal cell cancer. Side-effects were pronounced and the mean tolerated doses were 12.5 x 10(6) U/m2 interferon alpha three times per week and 0.10 mg/kg vinblastine once every three weeks. We observed a 43% response rate, with 1 complete remission, 8 partial remissions, 4 stabilizations and 8 progressions. These very encouraging results need to be confirmed by large scale studies.

Adenocarcinoma↗
PubMed1987

[Medical treatment of metastatic cancer of the kidney with a combination of vinblastine and recombinant interferon alpha IIa. Result of a phase I-II trial].

Usual treatments of metastatic renal cell carcinoma are not efficient. Phase II trials using Interferon alpha showed a low response rate (10 to 15%). We have conducted a phase I-II trial using a combination of Vinblastine and Recombinant alpha 2 A Interferon in 21 patients. The response rate is of 43% including 1 complete and 8 partial remissions, 5 stabilizations and 8 progressive diseases. In spite of important side effects, these results are promising.

Adult↗
PubMed1983

[Anaerobic gangrene in the edges of a segmental hysterotomy. Severe infectious complication of a cesarean section. Sequelae. Apropos of a recent case].

The infection of the edges of a hysterotomy wound by anaerobic bacteria is a very rare and dangerous complication of Caesarean section. Early surgical intervention with trimming of the edges and the institution of drainage together with suitable antibiotic treatment led to recovery. A second pregnancy, which unfortunately ended with a premature delivery, resulted after this conservative surgical procedure.

Adult↗
PubMed1981

[Congenital choledochal cyst. The value of systematic ultrasound screening starting in the second trimester of pregnancy (author's transl)].

Routine obstetrical ultrasound carried out in the 20th week of amenorrhoea made it possible to identify a septate abdominal cyst which was non-urinary in origin and situated in the right hypochondrium. It was difficult, armed with this information, to be sure from which organ the cyst derived. The secondary diagnosis of a congenital cyst of the bile duct was made at laparotomy carried out a few hours after birth.

Adult↗